David Angeloni,
Chief Science Officer,
Millennium Medical Technologies Inc
David Angeloni is Chief Scientist of Millennium Medical Technologies and Lead Scientist for AQ Skin Solutions. His career started as a clinical scientist at U.S. Labs in Irvine, California, where he played a key role in starting its genetics division and which eventually lead to the company being acquired by Laboratory Corporation of America in 2005 for $162 million. Since then, he has been either employed by or consulted for several biotech companies, including; ChromaVision Medical Systems (now Clarient), Alliance Medical Products (a Siegfried Company), and MP Biomedicals, LLC. David has also been a part of creating several patents held by Vysis (now owned by Abbot Laboratories) and working in the field of clinical diagnostics at Applied Imaging (later owned by Genetix before its acquisition by Molecular Devices, Inc.). He has extensive knowledge in the field of regenerative medicine, having presented and published 12 peer reviewed abstracts with colleagues regarding the clinical use of growth factors or adipose derived stem cells over the past 5 years. He holds a B.S. in Biology and a M.S. in Biological Sciences with an emphasis on microbiology, molecular genetics, and pathology, and holds a Ph.D. “all but dissertation” status in academia which he plans to complete soon.
Adipose Derived Regenerative Medicine: An Examination into the Point of Care Model Today
Monday, 9 November 2015 at 16:20
Add to Calendar ▼2015-11-09 16:20:002015-11-09 17:20:00Europe/LondonAdipose Derived Regenerative Medicine: An Examination into the Point of Care Model TodayClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Since the published discovery of adult pluripotent stem cells in adipose in 2002, scientists and physicians alike have been researching new methods of harvesting, isolating, identifying, expanding, and applying these cells in a clinical setting. As such, we have seen an explosion over the past five years with in-clinic use of these cells in an autologous, point of care model with many different companies offering a device or process, and claiming their final product superior. This makes the responsibilities of the physician in the clinic not only as chief medical but science and procurement officer a daunting process to uphold. In this talk, we take an objective stance; informing the listener the background behind the discovery of adipose derived stem cells, relevant publications and information concerning their isolation and characterization, and closing with tangible, science based concepts that should be considered when deploying these cells during a surgical procedure.
Add to Calendar ▼2015-11-09 00:00:002015-11-10 00:00:00Europe/LondonClinical and Surgical Translation of Adult Stem CellsClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-11-09 16:20:002015-11-09 17:20:00Europe/LondonAdipose Derived Regenerative Medicine: An Examination into the Point of Care Model TodayClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
